<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657796</url>
  </required_header>
  <id_info>
    <org_study_id>HFNCWEANINGMODE</org_study_id>
    <nct_id>NCT04657796</nct_id>
  </id_info>
  <brief_title>Role of High Flow Nasal Oxygen as a Strategy for Weaning From Invasive Mechan</brief_title>
  <official_title>Role of High Flow Nasal Oxygen as a Strategy for Weaning From Invasive Mechan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the Efficacy of high flow nasal oxygen as a weaning strategy in mechanically&#xD;
      ventilated patients with respiratory failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory failure is a main cause of IMV and admission to intensive care unit&#xD;
      (ICU){1}.&#xD;
&#xD;
      The day of extubation is a critical time during an intensive care unit (ICU) stay because in&#xD;
      case of postextubation failure {2},which reach to 25 - 40% from extubated patient associated&#xD;
      with VAP and barotrauma, mortality rate and hospital stay will increase , we use Adjuvant&#xD;
      oxygen therapy to prevent these undesirable event like COT ,NIV and High-flow nasal cannula&#xD;
      (HFNC) which can be used as an initial weaning strategy from IMVdue to its physiologic&#xD;
      benefits [3-4].&#xD;
&#xD;
      HFNC devices supply between 30 and 60 L/min of a controlled mixture of actively warmed (32-37&#xD;
      Â°C) and humidified (up to 100% relative humidity) oxygen and air through modified nasal&#xD;
      prongs. producing {5-6-7}:&#xD;
&#xD;
        1. moderate positive end-expiratory pressure (PEEP) .&#xD;
&#xD;
        2. HFNC might help prevent extubation failure through different&#xD;
&#xD;
      Mechanisms:&#xD;
&#xD;
        1. First, the controlled oxygen concentration may reduce transient hypoxemic episodes .&#xD;
&#xD;
        2. Second, the high flow washes the nasopharyngeal dead space, thus reducing CO2&#xD;
           re-breathing; this effect reduces respiratory rate and minute ventilation .&#xD;
&#xD;
        3. Third, the small amount of PEEP may reduce lung collapse . c)enabling better gas&#xD;
           exchange and reduced work of breathing. d)in patients with chronic obstructive pulmonary&#xD;
           disease (COPD), this level of PEEP may counterbalance auto PEEP, further reducing the&#xD;
           work of breathing.&#xD;
&#xD;
      e) humidification may improve mucus drainage and reduce mucus retention, alleviating the&#xD;
      associated atelectasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 5, 2020</start_date>
  <completion_date type="Anticipated">December 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Is patient outcome in terms of survival or death at discharge.</measure>
    <time_frame>through study completion average 7 days.</time_frame>
    <description>evaluate the Efficacy of high flow nasal oxygen as a weaning strategy in mechanically ventilated patients with respiratory failure as regarding Hospitalization ,complications, oxygenation , reintubation rate, mortality rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay through study completion average 7 days ,Adverse events.</measure>
    <time_frame>through study completion average 7 days.</time_frame>
    <description>evaluate efficacy of high flow nasal cannula on duration of hospital stay, complications rate.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Respiratory Failure With Hypoxia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Cannula</intervention_name>
    <description>use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patient in respiratory ICU who mechanically intubated will be enrolled in study by&#xD;
        using high flow nasal oxygen as a weaning strategy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1- All adult patients who were admitted to our ICU requiring endotracheal intubation (ETI),&#xD;
        were eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-intubated patients or those with tracheostomy were excluded from the study.&#xD;
&#xD;
          2. those having neurological alteration unrelated to hypercapnoeic encephalopathy,&#xD;
             cranio-facial deformity, upper airway obstruction, cardiogenic pulmonary edema,&#xD;
             cardiogenic shock, acute myocardial infarction, pneumothorax, pulmonary neoplasm,&#xD;
             pulmonary thromboembolism, gastrointestinal bleeding, and post-operative respiratory&#xD;
             failure.&#xD;
&#xD;
          3. Patients less than 18 y.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzan Sl Sayed, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hamed Fr Qenawy, Bachelor</last_name>
    <phone>01061812045</phone>
    <email>hamedfarrag216@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doaa Mo Magdy, Lecturer</last_name>
    <phone>01006261010</phone>
    <email>doaamagdy_2020@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Papazian L, Corley A, Hess D, Fraser JF, Frat JP, Guitton C, Jaber S, Maggiore SM, Nava S, Rello J, Ricard JD, Stephan F, Trisolini R, Azoulay E. Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. Intensive Care Med. 2016 Sep;42(9):1336-49. doi: 10.1007/s00134-016-4277-8. Epub 2016 Mar 11. Review.</citation>
    <PMID>26969671</PMID>
  </reference>
  <reference>
    <citation>Helviz Y, Einav S. A Systematic Review of the High-flow Nasal Cannula for Adult Patients. Crit Care. 2018 Mar 20;22(1):71. doi: 10.1186/s13054-018-1990-4. Review.</citation>
    <PMID>29558988</PMID>
  </reference>
  <results_reference>
    <citation>Drake MG. High-Flow Nasal Cannula Oxygen in Adults: An Evidence-based Assessment. Ann Am Thorac Soc. 2018 Feb;15(2):145-155. doi: 10.1513/AnnalsATS.201707-548FR. Review.</citation>
    <PMID>29144160</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hamed Farag Qenawy Ahmed</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

